@entity5230 inhibits the growth of an @entity420 isograft in Fischer XXXX .

@entity5230 @entity5 @entity1421 @entity35 @entity420
The effect of @entity5230 , a nonsteroidal anti-inflammatory drug, on a transplantable @entity420 in Fischer @entity35 was studied. Forty male Fischer @entity35 were injected with 1 X 10(6) DMH-F317 @entity420 cells, and after 2 weeks were assigned to be treated with @entity5230 or carrier solution. The groups were as follows: Group 1, control; Group 2, 4.0 mg/kg @entity5230 ; Group 3, 6.0 mg/kg @entity5230 ; and Group 4, 8.0 mg/kg @entity5230 . Thirty-nine of forty @entity35 developed measurable @entity5 during this study. At the conclusion, 60% (6/10) of the @entity35 in Group 2 were @entity5 free compared to 0/10 controls, 0/10 Group 3 @entity35 , and 1/8 Group 4 @entity35 . (P less than 0.005, chi 2). Mean @entity5 volumes (mm3) were calculated for each group and converted to log10. At Week 6, the mean log10 @entity5 volume (+/- SEM) for Group 2 was 1.5 +/- 0.6 vs 4.1 +/- 0.1 for Group 1 (P less than 0.05). The mean log10 volume for Group 3 was 3.8 +/- 0.1 (P less than 0.05 vs Group 2). The mean log10 volume for Group 4 was 3.4 +/- 0.05 and was not significantly different from that for Group 2 (P greater than 0.05). Plasma @entity1421 levels for each treatment group were determined at the conclusion of the study and no statistical difference between treatment groups was found. It is concluded that @entity5230 inhibits @entity5 growth in this model, and may have a role as a biological response modifier in @entity5 therapy.
